Dengue and Zika Virus Diagnostic Testing for Patients with a Clinically Compatible Illness and Risk for Infection with Both Viruses
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields



Publication Date Range:


Document Data


Document Type:






Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page


Dengue and Zika Virus Diagnostic Testing for Patients with a Clinically Compatible Illness and Risk for Infection with Both Viruses

Filetype[PDF-695.42 KB]

  • English

  • Details:

    • Alternative Title:
      MMWR Recomm Rep
    • Description:
      Dengue and Zika Viruses are closely related mosquitoborne flaviViruses with similar Transmission cycles, distribution throughout the tropics and subtropics, and disease manifestations including fever, rash, myalgia, and arthralgia. For patients with suspected dengue or Zika Virus disease, nucleic acid amplification tests (NAATs) are the preferred method of Diagnosis. Immunoglobulin M (IgM) antibody tTesting can identify additional infections and remains an important tool for the Diagnosis of these Diseases, but interpreting the results is complicated by cross-reactivity, and determining the specific timing of infection can be difficult. These limitations are a particular challenge for pregnant women in determining whether Zika Virus infection occurred during or before the pregnancy.This report summarizes existing and new guidance on dengue and Zika Virus diagnostic tTesting for patients with a clinically compatible illness who live in or recently traveled to an area where there is risk for infection with both Viruses. CDC recommendations for screening of asymptomatic pregnant women with possible Zika Virus exposure are unchanged. For symptomatic nonpregnant persons, dengue and Zika Virus NAATs should be performed on serum collected ≤7 days after symptom onset. Dengue and Zika Virus IgM antibody tTesting should be performed on NAAT-negative serum specimens or serum collected >7 days after onset of symptoms. For symptomatic pregnant women, serum and urine specimens should be collected as soon as possible within 12 weeks of symptom onset for concurrent dengue and Zika Virus NAATs and IgM antibody tTesting. Positive IgM antibody test results with negative NAAT results should be confirmed by neutralizing antibody tests when clinically or epidemiologically indicated, including for all pregnant women. Data on the Epidemiology of Viruses known to be circulating at the location of exposure and clinical findings should be considered when deciding which tests to perform and for interpreting results.Patients with clinically suspected dengue should receive appropriate management to monitor and treat shock and hemorrhage. Women with laboratory evidence of possible Zika Virus infection during pregnancy and their infants should be evaluated and managed for possible adverse outcomes. Dengue and Zika Virus disease are nationally notifiable conditions, and cases should be reported to public health authorities.
    • Pubmed ID:
    • Pubmed Central ID:
    • Document Type:
    • Main Document Checksum:
    • File Type:

    You May Also Like

    Checkout today's featured content at